Norway

Norway's primary regulatory authority for health products is the Norwegian Medicines Agency (Statens legemiddelverk, NOMA), which oversees the approval and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and digital health solutions. As a member of the European Economic Area (EEA), Norway is fully integrated into the European regulatory framework and applies EU legislation through the EEA Agreement. Pharmaceuticals are regulated under the Norwegian Medicines Act (Legemiddelloven) and its associated regulations, while medical devices fall under the EU Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746), which Norway has adopted. Marketing authorisations for pharmaceuticals can be obtained via the European Medicines Agency (EMA) centralised procedure, the mutual recognition procedure (MRP), or the decentralised procedure (DCP), all of which are accessible to Norway as an EEA state. NOMA also participates in the EMA's scientific and regulatory committees, giving it a direct role in European-level decision-making.

Applications for marketing authorisation must follow the Common Technical Document (CTD) format, which is the accepted standard across the EEA. A local Norwegian or EEA-based marketing authorisation holder or representative is required for all registered products. Medical devices must bear CE marking issued by a notified body, and manufacturers must register with relevant EU or EEA databases such as EUDAMED. Digital health solutions and software as a medical device (SaMD) are assessed under the MDR framework, with NOMA providing guidance on classification. Notable recent developments include Norway's ongoing implementation of the MDR and IVDR transition timelines, increased scrutiny of real-world evidence submissions, and active participation in the European HTA Regulation (EU 2021/2282) joint clinical assessment process, which Norway has opted into, streamlining health technology assessment at the European level.

Norway operates a highly centralised public healthcare procurement system underpinned by its universal, publicly funded model administered through the Ministry of Health and Care Services (Helse- og omsorgsdepartementet). The four regional health authorities (Helse Nord, Helse Midt-Norge, Helse Vest, and Helse Sor-Ost) are responsible for specialist and hospital care, and procurement of pharmaceuticals and medical devices at the hospital level is largely coordinated through the national procurement entity Sykehusinnkjop HF (Hospital Procurement HF), which conducts national and regional tenders on behalf of all public hospitals. Public procurement must comply with the Norwegian Public Procurement Act (Lov om offentlige anskaffelser) and EU procurement directives transposed through the EEA Agreement, ensuring open, competitive, and transparent tendering processes. For pharmaceuticals reimbursed in the primary care setting, the Norwegian Health Economics Administration (Helfo) manages the reimbursement list (Blaa Liste), and pricing is subject to reference pricing benchmarked against a basket of EEA countries, with negotiations conducted by NOMA and the Directorate of Health.

Norway is a high-income country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for domestic healthcare needs. The private healthcare market is relatively small compared to the dominant public sector, with private hospitals and clinics conducting their own procurement independently. However, Norway is a significant donor to global health initiatives and contributes substantially to Gavi, the Global Fund, and other multilateral health programmes, influencing procurement standards internationally. There are no formal local manufacturing preference policies in Norwegian public procurement, as EEA non-discrimination rules apply. Nonetheless, sustainability criteria and life-cycle costing are increasingly incorporated into tender evaluations, and the government has signalled growing interest in supply chain resilience and domestic or European manufacturing capacity for critical health products following lessons learned from the COVID-19 pandemic.